For instance, one pre-clinical study showed that EZH2 inhibition dramatically enhanced CRPC cells to genotoxic stress, demonstrating the potential utility in EZH2 inhibitors in sensitizing cancers that overexpress EZH2-activated DDR genes to genotoxic agents (157). The gene discussed is EZH2; the disease is cancer.